Back to research feed

Cancer discovery

October 13, 2026 · via Europe PMC

Mutability Dependence of Breast Cancer Metastasis and Latency to Recurrence.

Lawrence-Paul MR, Pan TC, Pant DK, +6 more, Chodosh LA

Journal ArticleAbstract only — full text under license

AI summary — for doctors, generated from the abstract only

Many metastasis-specific mutations in breast cancer arise after dissemination, and their timing explains much of the variation in time to recurrence.

What was studied

A genomic analysis of 662 paired and about 6000 unpaired primary and metastatic breast tumours.

Key findings

  • Metastasis-specific mutations were frequently acquired after dissemination, with a major APOBEC contribution.
  • 95% of patients had such mutations within a minimum set of 10 pathways.
  • More than half of the variation in latency was explained by timing of mutation acquisition within these pathways.

Clinical relevance

Oncologists may eventually use these pathways to understand late recurrence and identify therapeutic targets in metastatic disease.

Who should care

Medical Oncology

Limitations

The findings are computational and correlative, based on retrospective genomic datasets, so causality is inferred rather than shown.

This is mechanistic research that supports a model of metastasis but does not yet change patient care.

This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.

Abstract

To evaluate the functional relevance of mutations newly detected in breast cancer metastases, we analyzed genomic data from 662 paired and ~6,000 unpaired primary and metastatic tumors. These analyses indicate that metastasis-specific mutations are frequently acquired post-dissemination, with a disproportionate contribution from APOBEC-mediated mutagenesis. Metastasis-specific mutations converged on a set of pathways that were highly recurrent, distinct from those altered in primary tumors, and dependent on metastatic site. 95% of patients harbored metastasis-specific mutations within a minimum set of 10 pathways. Remarkably, more than half the variation in metastatic latency across patients was explained by the relative timing of mutation acquisition within implicated pathways before versus after dissemination. These findings support a "mutability-dependent" model of metastasis in which functionally consequential mutations accumulate after primary tumor dissemination and contribute to metastatic outgrowth, with latency reflecting the time required for DTCs to acquire the remaining driver mutations needed to achieve metastatic competence.

DOI

10.1158/2159-8290.CD-25-2090

PMID

42867316

Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.

Want more like this?

Browse more from the feed. A free account unlocks the full feed, saving and communities.

Back to the research feed

Create a free account · Sign in